Cerebrovascular Disorders Clinical Trial
Official title:
Human Cerebral Blood Flow Regulation: Sex, Mechanism, and Stress Differences (Phase 2)
Twenty-six otherwise healthy adults between 18-40 years of age composed of 13 males and 13 females will be enrolled in this study to determine how sex and sex hormones influence cerebral blood flow (CBF) control in healthy young adults without confounds of age or disease. Participants can expect to be on study for approximately 16 days.
Status | Recruiting |
Enrollment | 26 |
Est. completion date | May 31, 2026 |
Est. primary completion date | March 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Age between =18 - =40 years inclusive - Completed Phase 1: Study 2020-0336 Exclusion Criteria: - Hypertensive - > 125 mmHg systolic blood pressure; or - > 80 mmHg diastolic blood pressure - BMI =25 kg/m2 - Fasting blood glucose =100 mg/dl - LDL cholesterol =130 mg/dl - Triglycerides =150 mg/dl - Current diagnosis or history of: - peripheral vascular disease - hepatic disease - renal disease - lung disease - gastrointestinal disorders/bleeding - hematologic disease - stroke - myocardial infarction - coronary heart disease - congestive heart failure - heart surgery - prediabetes - diabetes mellitus (type 1, type 2, MODY, or others) - sleep apnea - hypertension - some autoimmune diseases, such as inflammatory bowel disease or systemic lupus erythematosus (exclusion at discretion of reviewing MD) - Current smoking, defined as the use of tobacco or nicotine products >5 times in the past 30 days. - Cardiovascular medication use - NSAID sensitivity - Magnesium-restricted diet - Any contraindications of having an MRI - (e.g. the requirement of anxiolytics in order to complete an MRI scan) - Irregular menstrual cycle (females only) - Medical conditions that can affect the menstrual cycle, such as hyperprolactinemia, prolactinoma, hypercortisolemia, and congenital adrenal hyperplasia (females only) - Pregnancy, breast feeding, or plans to conceive within the next 3 months (females only) - Polycystic ovary syndrome (females only) - Hirsutism defined as unwanted and/or excessive hair growth on the face, chest, or back (females only) - Levonorgestrel intrauterine device (IUD) (females only) - Hormonal birth control will not be allowed in women, in order to control for high variability between type, dose, and route of therapy. However, in discussion with Dr. Davis (Co-I) and Dr. Laura Cooney M.D., physician experts in medical and reproductive endocrinology and infertility, there are two broad exceptions to this birth control criteria: - Copper intrauterine devices (IUDs) will be allowed as they do not change systemic sex hormone levels). - Women currently taking hormonal birth control (i.e. contraceptive pills, patch, ring) for contraception only (not for a medical condition such as those listed in exclusion criteria above) may consider temporarily stopping to become eligible for enrollment. Hormonal birth control must be stopped at least one month prior to Study Visit 1 to provide time for menstruation to resume. Then stoppage continues through the last planned study visit. Screening information will be reviewed by endocrinology physicians to determine eligibility and timing on this issue. |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cerebral Blow Flow (CBF): Hormone Suppression Hypoxia Condition | Hypoxia condition will be measured twice via MRI during the first set of study visits under hormone suppression. Reported here is the CBF under hypoxia for the placebo group as compared to the CBF under hypoxia for the Indo group. | first set of study visits (up to 2 hours) within the first 7 days on study | |
Primary | Cerebral Blow Flow: Hormone Suppression Hypercapnia Condition | Hypercapnia condition will be measured twice via MRI during the first set of study visits under hormone suppression. Reported here is the CBF under hypercapnia for the placebo group as compared to the CBF under hypercapnia for the Indo group. | first set of study visits (up to 2 hours) within the first 7 days on study | |
Primary | Cerebral Blow Flow: Hormone Add-Back Hypoxia Condition | Hypoxia condition will be measured twice via MRI during the second set of study visits under hormone add-back. Reported here is the CBF under hypoxia for the placebo group as compared to the CBF under hypoxia for the Indo group. | second set of study visits (up to 2 hours) within 12-16 days on study | |
Primary | Cerebral Blow Flow: Hormone Add-Back Hypercapnia Condition | Hypercapnia condition will be measured twice via MRI during the first set of study visits under hormone add-back. Reported here is the CBF under hypercapnia for the placebo group as compared to the CBF under hypercapnia for the Indo group. | second set of study visits (up to 2 hours) within 12-16 days on study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03239847 -
Cost Effectiveness of the EndoPhys Pressure Sensing Access System vs. Radial A-line for Intra-operative Blood Pressure Monitoring
|
N/A | |
Recruiting |
NCT03544801 -
Renji Cerebral Small Vessel Disease Corhort Study
|
||
Recruiting |
NCT06010823 -
Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants
|
N/A | |
Withdrawn |
NCT04991038 -
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
|
N/A | |
Recruiting |
NCT02472028 -
Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals
|
Phase 4 | |
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Active, not recruiting |
NCT01555411 -
Akershus Cardiac Examination (ACE) 1950 Study
|
||
Completed |
NCT01304576 -
Orientation Agnosia: Clinical and Anatomical Study
|
N/A | |
Completed |
NCT00049920 -
The ARIC MRI Study
|
N/A | |
Completed |
NCT00049894 -
Predictors of Recurrent Stroke in the PROGRESS Study
|
N/A | |
Completed |
NCT00059293 -
Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
|
||
Completed |
NCT00005562 -
Coronary Artery Calcium, Exercise Tests, and CHD Outcome
|
N/A | |
Completed |
NCT00005395 -
Honolulu Heart Program-Study of Stroke and Dementia
|
N/A | |
Completed |
NCT00000479 -
Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer
|
Phase 3 | |
Completed |
NCT00005140 -
Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago
|
N/A | |
Enrolling by invitation |
NCT00005485 -
The Jackson Heart Study of Cardiovascular Disease Among African Americans
|
||
Recruiting |
NCT06275113 -
BRING-UP Prevention
|
||
Completed |
NCT02702635 -
Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging
|
N/A | |
Recruiting |
NCT04336852 -
Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function
|
N/A | |
Not yet recruiting |
NCT05892510 -
Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke
|
Phase 2/Phase 3 |